Source: Citybizlist

Finch: Finch Announces Reverse Stock Split of Common Stock

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc. (Nasdaq: FNCH), a microbiome technology company with a portfolio... Read MoreThe post Finch Announces Reverse Stock Split of Common Stock appeared first on citybiz.

Read full article »

Finch's Competitors | Finch's News | Finch's Financials

Followers on Owler

Annual Revenue

$100K-5.0M

Employees

1-25

CEO

Matthew P. Blischak

CEO Approval Rating

82/100

Finch is a Massachusetts-based pharmaceutical company that researches and develops novel microbiome therapies for the treatment of autism spectrum disorders.